65,437 trials
Aortic Stenosis · Mitral Stenosis · Aortic Valve Insufficiency
Primary: Subjects With Structural Valve Deterioration — 1 Participants
Anaplastic Thyroid Cancer · Recurrent Thyroid Cancer
Primary: Confirmed Response Rate (Partial Response [PR] or Complete Response [CR]) Per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 Criteria — 13 percentage of…
Type II Refractory Celiac Disease (RCD-II) · In-situ Small Bowel T-cell Lymphoma
Primary: Percent Change From Baseline in the Percentage of Aberrant Intestinal Intraepithelial Lymphocytes With Respect to All Intraepithelial Lymphocytes — 2.45; 7.30 percent…
Asthma
Primary: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 3; 4; 4; 4 participants
Cataract · Astigmatism
Primary: Rate of Severe Visual Distortions — 3 Participants
COPD · Heart Failure · Cancer
Primary: Number of Completed Exit Interviews From Patients on Feasibility of Their Use of Their Narrative Integrated Into EHR — 20; 18 Participants
Head and Neck Neoplasms · Lung Neoplasms · Urinary Bladder Neoplasms
Primary: Progression-free Survival (PFS) — 2.3; 3.7; 3.6; 1.7 months
Leukemia, Myeloid, Acute
Primary: Number of Participants Who Achieved Composite Complete Response (CRc) (Intent-to-Treat Population) — 18; 18 Participants
Pain
Primary: Short Term Efficacy: Change in Pain Intensity as Assessed by Patient Self Report on Numerical Rating Scale — 3.8; 4.0; 3.6 Units on a scale — p=0.82
Asthma
Primary: Change in Adherence of Use of Patient Asthma Inhalers — -0.36 Change in puffs taken/prescribed per wk
Mitochondrial Myopathy
Primary: Change in Distance Walked (Meters) on the 6-minute Walk Test (6MWT) — 13.5; 36.5; 64.5; 20.4 meters
Peripheral Arterial Disease · Lower Extremity Arterial Disease
Primary: Primary Outcome - Freedom From Acute Death, Freedom From 36-month Amputation, and Freedom From 36-month Clinically-driven Target Lesion Revascularization — 15; 23; 24…
Non-small Cell Lung Cancer Stage IV
Primary: Progression Free Survival Rate — 4; 0 Participants
Influenza · Healthy
Primary: Percentage of Participants Reporting Fever (Oral Temperature >= 101 Degrees Fahrenheit) Through Day 8 — 0; 0 Percentage of participants
Glucose Intolerance
Primary: Percent Change From Baseline in Glucose Total Area Under the Concentration Curve 0 to 2 Hours (AUC 0-2 Hrs) for Meal Tolerance Test (MTT) at Week 8 — -2.42; -9.52…